November 5, 2024
Lungs in flat icon style

Bronchiolitis Obliterans Syndrome: An Overview of this Chronic Lung Disease

What is Bronchiolitis Obliterans Syndrome?

Bronchiolitis obliterans syndrome  (BOS), also known as obliterative bronchiolitis (OB), is a chronic lung disease characterized by a small airways obstructive disorder that leads to the damage and scarring of the bronchioles in the lungs. The bronchioles are the tiny air passages that allow air to flow to and from the alveoli, the air sacs in the lungs involved in gas exchange. Over time, scar tissue builds up inside these passageways and causes them to become completely blocked, or obliterated. This obstruction of the airways results in breathing difficulties and a decline in lung function.

Causes and Risk Factors

While the exact cause is unclear, Bronchiolitis Obliterans Syndrome most commonly develops after lung transplantation. The underlying mechanisms involve inflammation and injury to the airways caused by an abnormal response from the body’s immune system. Specific risk factors that increase the chances of developing BOS include:

– lung transplantation – About 20-50% of lung transplant recipients develop BOS within 5 years post transplant. The allograft lung is recognized as foreign by the recipient’s immune system.

– viral infections – Infection with viruses like adenovirus, Epstein-Barr virus, and cytomegalovirus put transplant recipients at higher risk.

– gastric acid reflux –
Reflux of stomach contents into the lungs can damage the airways over time.

– smoking – Cigarette smoke exposure exacerbates the inflammatory response in the lungs.

– Chronic graft-versus-host disease – Occurs in some stem cell and bone marrow transplant patients and can involve lung damage.

– Exposure to occupational dusts or pollutants.

– Pre-existing lung conditions like cystic fibrosis also raise the risk in transplant recipients.

Symptoms and Diagnosis

In the early stages, Bronchiolitis Obliterans Syndrome may cause only mild symptoms like cough or exertional dyspnea. However, as the disease progresses, symptoms worsen and include:

– Increased shortness of breath with activity or at rest
– Fatigue
– Dry cough
– Chest tightness
– Wheezing

Diagnosis requires a thorough examination, pulmonary function tests, chest x-rays or CT scans. Pulmonary function tests typically show reduced forced expiratory volume in one second (FEV1), which reflects the small airways obstruction. A decline in FEV1 greater than 20% from baseline levels in the absence of infection confirms the diagnosis of BOS.

Disease Stages and Progression

The International Society for Heart and Lung Transplantation has established a staging system for BOS:

– Stage 0 – FEV1 has declined <20% from baseline
– Stage 1 – FEV1 has declined 20-29%
– Stage 2 – FEV1 has declined 30-44%
– Stage 3 – FEV1 has declined ≥45%

Later stages are more severe, correlate with significantly worse long-term survival. Unfortunately, BOS is usually progressive once established, and can advance even with treatment. Complete airway obstruction and respiratory failure may develop over months to years.

Treatment and Management

While there is currently no cure for Bronchiolitis Obliterans Syndrome, treatment aims to slow its progression and control symptoms. Initial therapies typically involve:

– Augmenting immunosuppression with medications like tacrolimus, sirolimus, mycophenolate or anti-T cell antibody therapies to reduce rejection episodes and slow inflammation.

– Pulmonary rehabilitation to improve breathing techniques and build endurance.

– Bronchodilators for symptom relief, such as albuterol or ipratropium.

– Antibiotics as needed for respiratory infections.

More advanced cases may require:

– Intravenous immune globulin infusions for added immunosuppression.

– Lung volume reduction surgery to remove damaged portions of the lung.

– Retransplantation, but this option carries a poor long term prognosis.

– Oxygen therapy and ventilator support in end-stage disease.

With aggressive management, the 5-year survival of Bronchiolitis obliterans syndrome  can approach 50-60%. Unfortunately, no treatment is completely effective, and most patients ultimately succumb to respiratory failure. Research focuses on developing preventative strategies and exploring regenerative approaches.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it

About Author - Money Singh
+ posts

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.  LinkedIn Profile

About Author - Money Singh

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.  LinkedIn Profile

View all posts by About Author - Money Singh →